2022-501489-24-00招募中3 期
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 132
- 试验地点
- 42
- 主要终点
- Event-free survival (EFS) by blinded central assessment.
研究概览
简要总结
To compare the efficacy of axicabtagene ciloleucel versus standard of care therapy (SOCT), as measured by event-free survival (EFS).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •High-risk disease defined as an IPI score of 4 or 5 at initial diagnosis
- •Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).
- •Histologically confirmed LBCL based on 2016 World Health Organization (WHO) classification by local pathology lab assessment, including one of the following: a) Diffuse large B-cell lymphoma, NOS b) High-grade B-cell lymphoma (HGBL) (including HGBL with MYC and BCL2 and/or BCL6 rearrangements (DHL/THL) based on FISH analysis, and HGBL-NOS) Note: Transformed DLBCL from follicular lymphoma or from marginal zone lymphoma is eligible if no prior treatment with anthracycline-containing regimen.
- •Ann Arbor Stage III or IV disease.
- •Have received only 1 cycle of R-chemotherapy
- •At least 1 measurable lesion per the Lugano Classification {Cheson 2014} on anatomical imaging such as computed tomography (CT) imaging (functional imaging such as PET may not be used to identify a measurable lesion). A measurable lesion is defined as greater than 1.5 cm LDi for lymph node and greater than 1.0 cm LDi for extranodal lesion
- •Adequate tumor biopsy specimen available for central pathology review (detailed sample collection requirement is in central pathology laboratory manual).
- •Age 18 years or older.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at the time of randomization. Note: ECOG > 12 at diagnosis is acceptable.
- •Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function as indicated by: a) Absolute neutrophil count (ANC) ≥ 1000/μL b) Platelet count ≥ 75,000/μL c) Absolute lymphocyte count ≥ 100/μL d) Creatinine clearance (as estimated by any local institutional method) ≥ 60 mL/minute e) Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 x ULN if documented liver involvement of lymphoma f) Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert’s Syndrome or documented LBCL liver or pancreatic involvement where ≤ 3.0 times the ULN g) Left ventricular ejection fraction (LVEF) ≥ 50% and no evidence of clinically significant pericardial effusion, and no clinically significant abnormal electrocardiogram (ECG) findings h) No evidence of Grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] 5.0) or greater pleural effusion or ascites (subjects with Grade 1 ascites or pleural effusion are eligible) i) Baseline oxygen saturation > 92% on room air
排除标准
- •Any prior treatment for LBCL other than the 1 cycle of R-chemotherapy.
- •Females of childbearing potential who are pregnant or breastfeeding (due to potentially dangerous effects of the preparative chemotherapy on the fetus or infant).
- •Not willing to practice birth control from the time of consent through 12 months after the last dose of axicabtagene ciloleucel or SOCT.
- •The following WHO 2016 subcategories by local assessment: a) T-cell/histiocyte-rich LBCL b) Primary DLBCL of the CNS c) Primary mediastinal (thymic) LBCL d) B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma e) Burkitt lymphoma f)History of Richter’s transformation of chronic lymphocytic leukemia
- •In the investigator’s judgment, the subject is unlikely to complete all study-specific visits or procedures, including follow-up visits, or comply with the study requirements for participation
- •History of severe immediate hypersensitivity reaction attributed to aminoglycosides
- •Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple bacterial infections are permitted if responding to active treatment. Discussion with the Kite medical monitor is encouraged.
- •History of acute or chronic active hepatitis B or C infection. If there is a positive history of treated hepatitis B or hepatitis C, the viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
- •Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a CD4 count > 200 cells/uL. Note: HIV-positive subjects in Australia are not permitted regardless of active anti-retroviral therapy or undetectable blood viral load (Refer to 12.4.4).
- •Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted.
- •Presence of detectable cerebrospinal fluid (CSF)-malignant cells, brain metastases, or a history of central nervous system (CNS) involvement of lymphoma.
- •Presence of cardiac atrial or ventricular lymphoma involvement.
- •Presence of CNS disorder such as dementia, autoimmune disease with CNS involvement, cerebral edema with confirmed structural defects by appropriate imaging, or seizure disorders requiring active anticonvulsive medication. History of stroke, transient ischemic attack, or posterior reversible encephalopathy syndrome (PRES) within 12 months prior to enrollment.
- •History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease free for at least 3 years
- •History of autologous or allogeneic stem cell transplant (SCT)
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, or other clinically significant cardiac disease within 12 months before enrolment.
- •Presence of primary immunodeficiency.
- •History of any medical condition including but not limited to autoimmune disease (eg, Crohn’s disease, rheumatoid arthritis, systemic lupus) requiring maintenance systemic immunosuppression/systemic disease modifying agents within the last 2 years. Endocrine conditions that require maintenance with physiologic dose steroids are allowed.
- •History of non-line associated, clinically significant (CTCAE 5.0 Grade 2 or greater) deep vein thrombosis or pulmonary embolism requiring therapeutic anticoagulation within 6 months of randomization.
- •Any medical condition or residual toxicities from prior therapies per investigator assessment likely to interfere with assessment of safety or efficacy of study treatment
- •History of severe immediate hypersensitivity reaction to any of the agents used in this study, including the lymphodepletion chemotherapy (cyclophosphamide or fludarabine).
- •Receipt of live vaccine ≤ 6 weeks before randomization and/or anticipation of need for such a vaccine during the subject’s participation in the study.
研究组 & 干预措施
-
Auxiliary
Participants receiving -
干预措施: - (Drug)
结局指标
主要结局
Event-free survival (EFS) by blinded central assessment.
Event-free survival (EFS) by blinded central assessment.
次要结局
- Progression-free survival (PFS) by blinded central assessment.
- Overal survival (OS)
- PFS by investigator assessment.
- Complete remission (CR) rate by blinded central assessment.
- Incidence of adverse events (AEs), serious adverse events (SAEs), deaths, and clinically significant changes in safety laboratory values
- Patient-reported outcome (PRO)-QOL as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Non-Hodgkin Lymphoma High Grade Module (EORTC QLQ-NHL-HG29), and European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L).
研究者
EU CT Support
Scientific
Kite Pharma Inc.
研究点 (42)
Loading locations...
相似试验
招募中
2 期
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease.2024-512978-99-00Syndax Pharmaceuticals Inc.67
招募中
1 期
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF MutationsNCT07288580Shanghai Euhearing Therapeutics Co., Ltd30
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
招募中
3 期
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85
招募中
2 期
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis2024-517356-35-00Citryll B.V.77